| Dr Shasta B Helsel, MD | |
|
301 Med Tech Pkwy Ste 180, Johnson City, TN 37604 | |
| (423) 794-5540 | |
| (423) 926-3187 |
| Full Name | Dr Shasta B Helsel |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 301 Med Tech Pkwy Ste 180, Johnson City, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750461265 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 2009-01551 (North Carolina) | Secondary |
| 208000000X | Pediatrics | P7929 (Texas) | Secondary |
| 208000000X | Pediatrics | 45407 (Tennessee) | Primary |
| Entity Name | Synergy Healthcare Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356584544 PECOS PAC ID: 9133271216 Enrollment ID: O20090721000415 |
News Archive
Canadian researchers have found that maternal multiple sclerosis (MS) is generally not associated with adverse delivery outcomes or risk to their offspring. Full findings now appear in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association.
ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that study results published in the January 2010 Annals of Thoracic Surgery demonstrated that coronary artery bypass graft (CABG) patients who undergo Endoscopic Vessel Harvesting (EVH) demonstrate similar long-term clinical outcomes as patients who undergo traditional "open" vein harvest (OVH) but have significantly reduced rates of leg infection.
Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shasta B Helsel, MD Po Box 3889, Johnson City, TN 37602-3889 Ph: (423) 794-5540 | Dr Shasta B Helsel, MD 301 Med Tech Pkwy Ste 180, Johnson City, TN 37604 Ph: (423) 794-5540 |
News Archive
Canadian researchers have found that maternal multiple sclerosis (MS) is generally not associated with adverse delivery outcomes or risk to their offspring. Full findings now appear in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association.
ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that study results published in the January 2010 Annals of Thoracic Surgery demonstrated that coronary artery bypass graft (CABG) patients who undergo Endoscopic Vessel Harvesting (EVH) demonstrate similar long-term clinical outcomes as patients who undergo traditional "open" vein harvest (OVH) but have significantly reduced rates of leg infection.
Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.
› Verified 5 days ago
John William Schweitzer, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 325 N State Of Franklin Rd, Ground Floor, Johnson City, TN 37604 Phone: 423-439-7320 | |
Mrs. Priya Narayanan Jain, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 325 N. State Of Franklin Road, Ground Fl, Johnson City, TN 37604 Phone: 423-439-7320 | |
Jodi B Gage, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 325 N. State Of Franklin Road, Ground Floor, Johnson City, TN 37604 Phone: 423-439-7320 Fax: 423-439-7343 | |
Dr. Demetrio Rebano Macariola Jr., MD Pediatrics Medicare: Medicare Enrolled Practice Location: 325 N State Of Franklin Rd, Ground Floor, Johnson City, TN 37604 Phone: 423-439-7320 Fax: 423-439-7343 | |
Karen E Schetzina, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 325 N State Of Franklin Rd, Ground Floor, Johnson City, TN 37604 Phone: 423-439-7320 Fax: 423-439-7343 | |
William Scott Dodd, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 325 N State Of Franklin Rd, Ground Floor, Johnson City, TN 37604 Phone: 423-439-7320 Fax: 423-439-7343 | |
Ahmad A Wattad, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 325 N State Of Franklin Rd, Ground Floor, Johnson City, TN 37604 Phone: 423-439-7320 Fax: 423-439-7343 |